Application No. 10/789,817 Babish, John G. Filed: February 27, 2004

## **REMARKS**

Claims 1-32 are pending and have been restricted under 35 U.S.C. § 121 into the following groups:

Group I: Claims 1-15, drawn to a composition comprising compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexahydroisoalpha acids, and a methylxanthine.

Group II: Claims 16-31, drawn to a composition comprising a compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexahydroisoalpha acids, and a curcuminoid.

Group III: Claim 32, drawn to a method of reducing inflammation comprising administering a composition of any of claims 1-31.

The Examiner has requested that one of the groups of claims be elected for examination. Applicants provisionally elect Group I, claims 1-15, drawn to a composition comprising compound selected from the group consisting of reduced isoalpha acids, tetra-hydroisoalpha acids, and hexahydroisoalpha acids, and a methylxanthine.

The restriction requirement is traversed with respect to division of the claims of Group I from the claim of Group III. While the claims of Group I may be patentably distinct, it is submitted that a thorough search of the claims of either group (as relating to the subject matter of claims 1-15) will likely reveal art relevant to the examination of the claims of the other group. Applicants request reconsideration of the Restriction Requirement for claim groups I and III and rejoin of method claim 32 (as it relates to claims 1-15) with composition claims of 1-15 should the compositions be found patentable.

As for claims in Group II, Applicants have withdrawn these claims but reserve the right to prosecute any subject matter of the previously presented claims 16-31 in one or more subsequent applications.

Application No. 10/789,817

Babish, John G.

Filed: February 27, 2004

The Examiner has additionally required that a species election be made. In response, Applicants elect, with traverse, tetra-hydroisoalpha acids.

In summary, Applicants elect Group I claims and select tetra-hydroisoalpha acids, with traverse. The Examiner is invited to contact the undersigned agent to discuss any issues or questions.

To the extend necessary, a petition for an extension of time under 37 C.F.R. § 1.136 is hereby made. Please grant any extension of time required to enter this response and charge any additional required fees to our deposit account 50-1133.

Respectfully submitted,

McDERMOTT, WILL & EMERY, LLP

Dated: December 18, 2007

Atabak R. Royaee, Reg. No. 59,037

McDERMOTT, WILL & EMERY, LLP

28 State Street

Boston, Massachusetts 02109-1775

Tel. (617) 535-4108 Fax: (617) 535-3800